Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations
N Koyama, Y Uchida - Anticancer Research, 2013 - ar.iiarjournals.org
Background: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …
Response to erlotinib after failure of gefitinib in non-small cell lung cancer with EGFR mutation
19072 Background: Non-small cell lung cancer (NSCLC) patients with epidermal growth
factor receptor (EGFR) mutation show excellent response to gefitinib, but eventually develop …
factor receptor (EGFR) mutation show excellent response to gefitinib, but eventually develop …
[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months
H Saito, S Murakami, T Kondo, F Oshita… - Oncology Research …, 2012 - karger.com
Background: There have been reports on the use of erlotinib in non-small cell lung cancer
(NSCLC) patients after gefitinib resistance occurs, and it has been stated that erlotinib may …
(NSCLC) patients after gefitinib resistance occurs, and it has been stated that erlotinib may …
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
DB Costa, KSH Nguyen, BC Cho, LV Sequist… - Clinical cancer …, 2008 - AACR
Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …
Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with …
GJ Riely, VA Miller, W Pao, M Zakowski… - Journal of Clinical …, 2005 - ascopubs.org
7085 Background: The EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib induce
significant regressions and improve survival in patients with NSCLC. Mutations in the EGFR …
significant regressions and improve survival in patients with NSCLC. Mutations in the EGFR …
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
A Horiike, N Yamamoto, H Tanaka… - Journal of Clinical …, 2010 - ascopubs.org
7573 Background: Gefitinib and erlotinib are two orally active epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) used in the treatment of advanced non-small …
receptor tyrosine kinase inhibitors (EGFR-TKIs) used in the treatment of advanced non-small …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
Long-term treatment with erlotinib for EGFR wild-type non-small cell lung cancer: A case report
G Polychronidou, P Papakotoulas - Case reports in oncology, 2013 - karger.com
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and
erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung …
erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung …
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
SH Cho, LC Park, JH Ji, S Park, DW Hwang… - Cancer chemotherapy …, 2012 - Springer
Purpose The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …